-
Ab181863-1mlApplication:WB: 1/1,000 - 1/10,000: Predicted molecular weight: 26.3 KDa.
-
Ab181863-50μlApplication:WB: 1/1,000 - 1/10,000: Predicted molecular weight: 26.3 KDa.
-
Ab181864-100μlApplication:WB: 1/1,000 - 1/100,000: Predicted molecular weight: 26.3 KDa.
-
Ab181864-10μlApplication:WB: 1/1,000 - 1/100,000: Predicted molecular weight: 26.3 KDa.
-
Ab181864-1mlApplication:WB: 1/1,000 - 1/100,000: Predicted molecular weight: 26.3 KDa.
-
Ab181864-50μlApplication:WB: 1/1,000 - 1/100,000: Predicted molecular weight: 26.3 KDa.
-
Ab090857-100μgMouse anti Human BCMA/CD269 Antibody, Monoclonal (HIBCMA), could be used for Flow and so on.Application:Flow:Protein Function:Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral
-
Ab090857-10μgMouse anti Human BCMA/CD269 Antibody, Monoclonal (HIBCMA), could be used for Flow and so on.Application:Flow:Protein Function:Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral
-
Ab090857-1mgMouse anti Human BCMA/CD269 Antibody, Monoclonal (HIBCMA), could be used for Flow and so on.Application:Flow:Protein Function:Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral
-
Ab090857-50μgMouse anti Human BCMA/CD269 Antibody, Monoclonal (HIBCMA), could be used for Flow and so on.Application:Flow:Protein Function:Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral
-
231047
BD TaxoT P Discs For differentiating Pneumococci, P (6/sp)
Price: $223.59List Price: $248.43Intended Use: Taxo&trade A discs are for the presumptive identification of group A beta-hemolytic streptococci based on susceptibility to a low level of bacitracin. Discs are intended for use with pure cultures, with the exception noted under -
Ab175465-100μgBebtelovimab (anti-Spike RBD) a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab (anti-Spike RBD) potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy.Purity≥95%